TriNetX LIVE™ Network Surpasses 300 Million Patients, Expanding Decision-Grade Evidence Across Global Healthcare
The milestone reflects accelerating international growth and gives pharmaceutical companies, academic researchers, healthcare providers, and health-tech innovators access to trusted, current, clinically rich, and globally representative real-world...
TriNetX Enhances its Ability to Federate Genomics Data Across its Global Network of Providers through the Acquisition of Key Assets of Zetta Genomics
TriNetX® will continue to support all existing Zetta Genomics customers utilizing the award-winning XetaBase® technology for research and patient care innovation CAMBRIDGE, Mass. and CAMBRIDGE, United Kingdom, April 7, 2026 /PRNewswire/ -- TriNetX,...
TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions
Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX's industry-leading global network of electronic health record data Collaboration will expand Regeneron's world-leading genomic and proteomic...
TriNetX and Fujitsu Launch Joint Venture to Increase Japanese Patients' Access to Life-Changing Medicines
Partnership taps real-world data to accelerate clinical trials, research, and drug development in Japan. CAMBRIDGE, Mass., Feb. 12, 2025 /PRNewswire/ -- TriNetX, a global leader in real-world data (RWD) and real-world evidence (RWE) solutions, has...